JUNS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast JUNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JUNS is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

25.00

Averages

25.00

High

25.00

Current: 0.000

Low

25.00

Averages

25.00

High

25.00

Greenridge

William Gregozeski

Buy

downgrade

$30 -> $25

2025-11-05

Reason

Greenridge

William Gregozeski

Price Target

$30 -> $25

2025-11-05

downgrade

Buy

Reason

Greenridge analyst William Gregozeski lowered the firm's price target on Jupiter Neurosciences to $25 from $30 and keeps a Buy rating on the shares after the company announced last week that it entered into a $20M Standby Equity Purchase Agreement with Yorkville Advisors. The firm added in the cash and dilutive impact from the initial $6M advance and is assuming the notes are repaid with stock at $1.50 per share, the analyst noted.

Valuation Metrics

The current forward P/E ratio for Jupiter Neurosciences Inc (JUNS.O) is -4.81, compared to its 5-year average forward P/E of -5.86. For a more detailed relative valuation and DCF analysis to assess Jupiter Neurosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.86

Current PE

-4.81

Overvalued PE

-3.29

Undervalued PE

-8.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

49.90

Current PS

34.26

Overvalued PS

86.39

Undervalued PS

13.41

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

JUNS News & Events

Events Timeline

No data

News

7.5

2025-12-23Globenewswire

Jupiter Neurosciences to Host Investor Webinar on January 6, 2026

3.5

2025-12-03Newsfilter

Jupiter Neurosciences Advances JOTROL™ into Phase 2a Parkinson's Trial and Launches Nugevia™ Brand

4.5

2025-11-24TipRanks

Daily Update on VTI ETF – November 24, 2025

People Also Watch

Frequently Asked Questions

What is Jupiter Neurosciences Inc (JUNS) stock price today?

The current price of JUNS is 1.06 USD — it has increased 2.91 % in the last trading day.

What is Jupiter Neurosciences Inc (JUNS)'s business?

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

What is the price predicton of JUNS Stock?

What is Jupiter Neurosciences Inc (JUNS)'s revenue for the last quarter?

Jupiter Neurosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Jupiter Neurosciences Inc (JUNS)'s earnings per share (EPS) for the last quarter?

Jupiter Neurosciences Inc. EPS for the last quarter amounts to -0.07 USD, increased 250.00 % YoY.

What changes have occurred in the market's expectations for Jupiter Neurosciences Inc (JUNS)'s fundamentals?

The market is revising No Change the revenue expectations for Jupiter Neurosciences, Inc. (JUNS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -30.72%.

How many employees does Jupiter Neurosciences Inc (JUNS). have?

Jupiter Neurosciences Inc (JUNS) has 4 emplpoyees as of January 10 2026.

What is Jupiter Neurosciences Inc (JUNS) market cap?

Today JUNS has the market capitalization of 36.49M USD.